Rush University Medical Center once again has been named one of the nation’s top hospitals, according to the new issue of U.S. News & World Report. Rush is ranked in seven of 16 categories included in the magazine’s 2014 -15 “America’s Best Hospitals” issue, which became available online on July 15, and is one of the two top-ranked hospitals in Illinois overall.
Rush’s orthopedics program was ranked No. 6 nationwide, making it the highest ranked orthopedics program in Illinois. Rush’s other ranked programs were geriatrics (No. 17); neurology and neurosurgery (No. 17); nephrology (No. 31); urology (No. 43); cardiology and heart surgery (No. 46); and cancer (No. 48).
U.S. News also noted that the following Rush specialty services are “high-performing”: diabetes and endocrinology; ear, nose and throat; gastroenterology; gynecology; and pulmonary.
Heart disease is never a welcome diagnosis. It can be particularly daunting for a patient who is already contending with cancer.
With both diseases becoming more and more prevalent, cases of crossover between them are becoming more of a problem. Such patients would benefit from specialized health care, and that’s why Dr. Kim Williams, who was appointed chief of cardiology at Rush in November, hopes to soon tailor a program to meet their particular needs.
Williams, a nuclear cardiologist with a special interest in cardiovascular radiology and heart disease in kidney and cancer patients, plans to soon establish a cardio-oncology clinic at Rush in collaboration with the Medical Center’s cancer programs. The clinic would provide care for two distinct groups of patients: those whose chemotherapy regimens put them at high risk for heart disease, and those who have both cancer and heart disease.
“In the coming years, cancer will overtake heart disease as the No. 1 killer of Americans,” Williams said. “But with the incidence of heart disease being what it is, there will be a lot of overlap between the two. And patients who have both conditions need specialized management.”
He hopes to add or expand services at Rush for several other groups of patients who need ongoing management: adults with congenital heart disease, patients with heart and renal problems, and patients with heart and metabolic conditions.
Researchers at Rush have identified the underlying mechanism of calcium-triggered cardiac arrhythmias, or irregular heartbeats. The discovery, described in the Jan. 19 issue of Nature Medicine, has major implications for the development of molecularly designed drugs specifically targeted at this form of arrhythmia.
The study was led by Wayne Chen, PhD, professor of molecular biophysics and physiology at Rush and professor of physiology and biochemistry at the University of Calgary-Libin Institute. Michael Fill, PhD, professor of molecular biophysics and physiology at Rush, collaborated on the research.
Cardiac arrhythmias can cause dizziness and fainting, or in severe cases, sudden death. While many factors, including genetics, contribute to the development of arrhythmias, research has shown that a common cause of cardiac arrhythmias is calcium overload. Calcium overload disrupts the finely controlled electrical activity governing contraction of heart muscle.
Calcium is stored inside cardiac cells, much like skeletal muscle cells, in preparation for contraction. The protein responsible for release of calcium is known as the cardiac ryanodine receptor (RyR2), or the calcium release channel, which acts like a safety valve that prevents calcium overload.
Beginning today, 22 senior cardiologists from Egypt are participating in a three-day workshop at Rush University Medical Center that includes lectures on leading-edge, non-invasive surgery techniques from Rush University faculty members.
The lectures will be complemented by case studies and the opportunity to remotely observe procedures being performed in the operating room. The visiting physicians will bring their new skills back to their respective home institutions to train other physicians to better serve their patients.
“Rush has renowned non-invasive and interventional cardiology labs and is adept at diagnosing and treating complex heart and vascular conditions,” said Dr. Neeraj Jolly, the workshop’s organizer and director of the section of invasive cardiology at Rush. “This event will allow us to train the trainer, giving these physicians a chance to bring what they learn back to their colleagues in their home country.”
Rapid, coordinated response to people with chest pain symptoms is critical to successful treatment of heart attacks.
Patients wait too long after the onset of heart attack symptoms before seeking medical care, according to the Society of Cardiovascular Patient Care. Even with advancements at hospitals, patients must still quickly recognize the signs and symptoms of a heart attack and take the first step toward getting help — particularly in December and January, when heart attack deaths peak.
Accredited Chest Pain Centers, such as Rush University Medical Center, are especially well-prepared to respond quickly to a person experiencing chest pains. In order to become accredited by the Society of Cardiovascular Patient Care, hospitals must meet or exceed a wide set of stringent criteria and demonstrate commitment to reducing the time it takes to receive treatment, and increase the accuracy and effectiveness of treatment in a coordinated process that can save lives.
In 2009, Rush became the first academic medical center in Chicago to earn the accreditation and was recently reaccredited.
One of the criteria for accreditation is to significantly reduce the time it takes for a patient experiencing symptoms of a possible heart attack to see a physician, thus reducing the time to treatment during the critical early stages when treatments are most effective. In addition, hospitals must create more effective systems to get patients into the catheterization lab so a blocked coronary artery can be opened in the shortest amount of time. Continue reading →
Filipino women between 40 and 65 years old can receive free screenings for cholesterol and diabetes while participating in a heart health study June 9 and 10 from 7 a.m. to 1 p.m. at Rush University Medical Center’s Heart Center for Women at 1725 W. Harrison St. in Chicago.
This 400-person study, an evaluation of the impact that factors such as genetics have on heart health, is specifically seeking women who don’t suffer from cancer, lupus, or acute or chronic inflammatory diseases. Blood will be drawn by licensed professions. A minimum of eight hours of fasting is required prior to the exam, which lasts 30 to 45 minutes.
Please bring all prescription and non-prescription medications. Refreshments will be provided.
An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered at Rush University Medical Center to patients with severe aortic stenosis who are at high-risk or not suitable candidates for open-heart, valve-replacement surgery.
“This breakthrough technology could save the lives of thousands of patients with heart valve disease who have no other therapeutic options,” says Dr. Ziyad Hijazi, director of the Rush Center for Congenital and Structural Heart Disease and interventional cardiologist of the Rush Valve Clinic. The treatment is offered through a multi-center, phase IIb cohort study called the PARTNER II (Placement of AoRTic traNscathetER valves) trial.
Aortic valve stenosis (AS) is a type of valvular heart disease characterized by an abnormal narrowing of the aortic valve opening. It is a condition that affects nearly 1.5 million Americans. It causes hardening or thickening of the aortic valve leaflets, which limits leaflet motion and obstructs oxygen-rich blood flow from the heart to the rest of the body. Patients with severe AS may have symptoms of chest pain, fatigue, shortness of breath, lightheadedness or fainting. Although AS typically progresses slowly without symptoms, once symptoms occur, treatment is required. Fifty percent of patients may not survive beyond one to three years.
Traditionally, patients with symptomatic AS undergo aortic valve replacement during an open-heart surgery to alleviate symptoms, improve survival and improve quality of life. However, many patients who are at very high risk for surgery, such as the elderly and frail individuals with multiple health concerns, are considered inoperable.